

SmartPA Criteria Proposal

Drug/Drug Class:	Emsam Clinical Edit
First Implementation Date:	May 16, 2007
Proposed Date:	September 16, 2021
Prepared for:	MO HealthNet
Prepared by:	MO HealthNet/Conduent
Criteria Status:	<input checked="" type="checkbox"/> Existing Criteria <input type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

Executive Summary

Purpose: Ensure appropriate utilization and control of Emsam® (selegiline transdermal)

Why Issue Selected: Emsam® is a transdermally administered version of selegiline, a monoamine oxidase inhibitor (MAOI). Emsam is indicated for the treatment of major depressive disorder. MAOIs are recognized as having broad efficacy in treating depressive disorders; however, despite their effectiveness, MAOI use is generally reserved for patients who do not respond to other treatments, primarily due to safety concerns, tolerability issues, and the requirement that patients follow a modified diet while taking these agents. MAOIs are associated with the risk of hypertensive crisis related to the ingestion and metabolism of tyramine-containing foods. At lower doses (6mg/24hr patch), Emsam is selective for MAO B and avoids first-pass hepatic metabolism; this allows for no dietary restrictions at the lower dose. However, the higher doses of Emsam (9mg/24hr and 12mg/24hr) are non-selective and inhibit both MAO A and MAO B, thus requiring the tyramine modified diet to reduce the risk of hypertensive crisis; these higher doses are typically required for antidepressant activity. Emsam offers a treatment option for patients not achieving satisfactory response with first-line agents, including SSRIs and SNRIs. Due to the high cost, possible adverse events, and specific approved indication, MO HealthNet will impose clinical criteria to ensure appropriate utilization of Emsam.

Program-Specific Information:

Date Range FFS 7-1-2019 to 6-30-2020			
Drug	Claims	Spend	Avg Spend per Claim
EMSAM 6 MG/24 HR PATCH	17	\$30,107.77	\$1,771.04
EMSAM 9 MG/24 HR PATCH	36	\$65,159.08	\$1,809.97
EMSAM 12 MG/24 HR PATCH	0	-	-

Type of Criteria: Increased risk of ADE Preferred Drug List
 Appropriate Indications Clinical Edit

Data Sources: Only Administrative Databases Databases + Prescriber-Supplied

Setting & Population

- Drug class for review: Emsam® (selegiline transdermal)

SmartPA Clinical Proposal Form

© 2021 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.

- Age range: All appropriate MO HealthNet participants aged 18 years and older

Approval Criteria

- Participant is aged 18 years or older **AND**
- Documented trial of a SSRI, SNRI, bupropion, or mirtazapine **OR**
- Documented compliance to previous Emsam therapy (defined as 90 days in the past 120 days)

Denial Criteria

- Therapy will be denied if all approval criteria are not met
- Daily dose exceeds 12 mg per day

Required Documentation

Laboratory Results:
MedWatch Form:

Progress Notes:
Other:

Disposition of Edit

Denial: Exception code "0682" (Clinical Edit)
Rule Type: CE

Default Approval Period

1 year

References

- EMSAM® (selegiline transdermal system) [package insert]. Morgantown, WV: Mylan Specialty L.P.; May 2020.
- Facts & Comparisons. Selegiline Transdermal. Accessed August 4, 2021.
- IPD Analytics. Behavioral Health: Depression. Accessed August 4, 2021.
- American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder - Third Edition. https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf. October 2010.

SmartPA Clinical Proposal Form

© 2021 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.